Cancer Biomarkers Players, products and prospects

EXECUTIVE SUMMARY

• Figure1: Growth in biomarker market 2007-2015
• What are biomarkers?
• Why are they important?
  • Figure 2: Potential impact of biomarkers on disease pathways
• What technologies are involved?
• What impact will biomarkers have on R&D?
  • Figure 3: Potential impact of biomarkers on R&D
• Who are the major biomarker players and in what research area?
• Cancer biomarker companies
• Cardiovascular biomarker companies
• CNS biomarkers companies
• Company Analysis Criteria
  • Biomarker technology & platforms
  • Association/clinical studies
  • Management strategy
  • Application & potential

CANCER MARKET & REVENUES

• Market revenues - global
  • Figure 1: Global cancer drugs sales (2007)
• Market revenues - leading brands
  • Figure 2: Leading cancer brands (2007)
• Market revenues - leading players
  • Figure 3: Top 10 oncology players (2007 revenues)
• CANCER EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT
• Epidemiology
  • Table 1: Cancer Statistics for four most common cancers, 2008
• Diagnosis
• Screening
  • Table 2: Cancer screening
• Current & future treatment
• Future treatment
  • Figure 4: Anticancer drugs in clinical development
• CANCER BIOMARKERS
  • Cancer biomarker R&D
    • Table 3: Types of biomarker
  • Known cancer biomarkers
    • Table 4: Commercially available known cancer biomarker diagnostics
  • Probable and possible valid cancer biomarkers
    • Table 5: Probable cancer biomarkers diagnostics
    • Table 6: Possible cancer biomarkers diagnostics
• CANCER BIOMARKER OPPORTUNITIES & CHALLENGES
  • Opportunities
  • Challenges
  • BIOMARKER MARKET
  • Biomarker market revenues - global
    • Figure 8: Global biomarker sales in 2007
  • Cancer biomarker market revenues - global
    • Figure 9: Global cancer biomarker sales in 2007
  • Future biomarker market revenues - global
    • Figure 10: Global biomarker sales in 2015
  • Future cancer biomarker market revenues - global
    • Figure 11: Global cancer biomarker sales in 2015
• CANCER BIOMARKER TRENDS
  • Table 7: Recent deals in oncology biomarkers
  • Pharma and specialty pharma deals
  • Collaborations with service providers
  • Collaborations with academics and consortia
• BIOMARKER ANALYSIS
  • DNA biomarkers
  • RNA and microRNA biomarkers
  • Proteomic biomarkers
• KEY BIOMARKER COMPANIES ANALYSED
• KEY BIOMARKER EVALUATION CRITERIA

CANCER BIOMARKER- COMPANY ANALYSIS

• Abbott Diagnostics
• Biomarker novelty & technology platform
  • Figure 12: Abbott' s UroVysion bladder cancer test
• Association studies/clinical data
• Pivotal Trial
  • Table 7: Comparison of UroVysion vs Cystoscopy/Histology for Detection of Bladder Cancer Recurrence by Stage and Grade*
• Management strategy
• Application & market potential
• Biomarker analysis
• Affymetrix
  • Biomarker novelty & technology platform
    • Figure 13: Affymetrix' approach to biomarker discovery, validation and clinical utility applications
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Agendia BV
  • Biomarker novelty & technology platform
  • Association studies/clinical data
    • Figure 14: MammaPrint Profile vs NIH Consensus Criteria
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• AltheaDx
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• AVEO Pharmaceuticals
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• AviaraDx
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• BG Medicine
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
    • Figure 15: BG Medicines Biomarker Programme
  • Application & market potential
  • Biomarker analysis
• Beckman Coulter
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• BioCurex
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Biomedical Diagnostics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Biomerica
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Bruker Daltonics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Caprion Proteomics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Clinical Data
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Celera
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Dako Denmark A/S
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• DxS Ltd.
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Epigenomics AG
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Epistem Plc
  • Biomarker novelty & technology platform
    • Figure 16: Epistem' s Biomarker Drug Development Programme
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• GeneNews
  • Biomarker novelty & technology platform
    • Figure 17: GeneNews' Sentinel Principle
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Fujirebio Diagnostics, Inc
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Genomic Health
  • Biomarker novelty & technology platform
    • Figure 18: Oncotype Dx test for invasive breast cancer
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Gen-Probe
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Genzyme Genetics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• InterGenetics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Ipsogen Therapeutics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
    • Figure 19: Oncotype Dx test for invasive breast cancer
  • Application & market potential
  • Biomarker analysis
• Laboratory Corporation of America
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Matritech
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Monogram Biosciences
  • Biomarker novelty & technology platform
    • Figure 20: VeraTag Assay
  • Association studies/clinical data
    • Figure 21: VeraTag Clinical Data: Bordet Cohort
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Orion Genomics
  • Biomarker novelty & technology platform
    • Figure 22: Orion' s MethylScope
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Oxford Genome Biosciences (UK) Ltd
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Power3 Medical Products
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
    • Figure 23: Powder3' s business strategy
  • Application & market potential
  • Biomarker analysis
• Predictive Biosciences
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Provista Life Sciences
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Quest Diagnostics
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Roche Diagnostics
  • Biomarker novelty & technology platform
    • Figure 24: Diagnostic marker candidate to a product
  • Association studies/clinical data
    • Figure 25: Biomarkers distinguish Leukaemia subclasses
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• SuperArray Bioscience Corporation
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Third Wave Technologies
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Upstream Biosciences
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Veridex, LLC
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis
• Vermillion
  • Biomarker novelty & technology platform
  • Association studies/clinical data
  • Management strategy
  • Application & market potential
  • Biomarker analysis

CANCER biomarker APPENDIX 1

• Table 8: Global biomarker sales 2007-20015E

CANCER biomarker APPENDIX 2

• Table 8: Global cancer biomarker sales 2007-20015E

CAncer biomarker APPENDIX 3

• Company Analysis Criteria
  • Biomarker technology & platforms
  • Association studies
  • Management strategy
  • Application & potential
    • Table 9: Key cancer biomarker companies
    • Figure 26: Leading Cancer Biomarker Companies - Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers

GLOSSARY

ACRONYMS

BIBLIOGRAPHY & end NOTES